Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 508 Results

Page 10 of 51« First «...8 91011 12...20 30 40...»Last »

May 9, 2024

DBV Technologies to Participate in Upcoming Investor Conferences

May 7, 2024

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

April 25, 2024

Combined General Meeting of May 16, 2024

April 4, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

March 8, 2024

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

March 7, 2024

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

March 4, 2024

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

February 20, 2024

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

January 16, 2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

December 4, 2023

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

Page 10 of 51« First «...8 91011 12...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top